,outcome,arm 1,arm 2
0,intervention,,
0,"incidence of adverse events, cytomegalovirus ( CMV ), total study group","10.1 %, 11.3 %, 17.9 %, 19.0 %, 25.2 %, 3.2 %, 32.5 %, 37.3 %, 5.7 %, 9.5 %","10.1 %, 11.3 %, 17.9 %, 19.0 %, 25.2 %, 3.2 %, 32.5 %, 37.3 %, 5.7 %, 9.5 %"
0,"incidence of adverse events, total study group","fever (, herpes simplex (, leukopenia (, noninduction ,","fever (, herpes simplex (, leukopenia (, noninduction ,"
